IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis
Open Access
- 1 January 2019
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 11
Abstract
Background: Apremilast (Otezla®) is a phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of psoriasis and psoriatic arthritis (PsA), but the reason why apremilast shows clinical effect is not fully understood. The objective of this study was to study the downstream effects of apremilast on cells of inflamed joints in immune-mediated inflammatory arthritis. Methods: Synovial fluid was obtained from patients with active rheumatoid arthritis (RA), PsA or peripheral spondyloarthritis (SpA; n = 18). The in vitro models consisted of synovial fluid mononuclear cells (SFMCs) or fibroblast-like synovial cells (FLSs) cultured for 48 h, SFMCs cultured for 21 days, an osteoclast pit formation assay, and a mineralization assay. Results: In SFMCs cultured for 48 h, apremilast decreased the production of interleukin (IL)-12/IL-23p40 (the shared subunit of IL-12 and IL-23), colony-stimulating factor 1, CD6, and CD40 and increased the production of C-X-C motif chemokine 5 dose-dependently. Apremilast had a very different response signature compared with the tumor necrosis factor alpha inhibitor adalimumab with a substantially greater inhibition of IL-12/IL-23p40. In SFMCs cultured for 21 days, apremilast increased the secretion of IL-10. In FLS cultures, apremilast decreased matrix metalloproteinase-3 production. Apremilast decreased osteoclastogenesis but did not affect mineralization by human osteoblasts. Conclusion: This study reveals the downstream effects of apremilast in ex vivo models of arthritis with a strong inhibition of IL-12/IL-23p40 by SFMCs. Our findings could explain some of the efficacy of apremilast seen in IL-12/IL-23-driven immune-mediated inflammatory diseases such as psoriasis and PsA.Keywords
Funding Information
- Kongelig Hofbuntmager Aage Bangs Fond
- The Nygaard foundation
- Augustinus Fonden
This publication has 30 references indexed in Scilit:
- Decreased plasma levels of soluble CD18 link leukocyte infiltration with disease activity in spondyloarthritisArthritis Research & Therapy, 2014
- Phosphodiesterase 4-targeted treatments for autoimmune diseasesBMC Medicine, 2013
- Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseasesTherapeutic Advances in Musculoskeletal Disease, 2010
- Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritisArthritis Research & Therapy, 2010
- Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasisBritish Journal of Pharmacology, 2010
- PDE4 inhibitor upregulates PTH‐induced osteoclast formation via CRE‐mediated COX‐2 expression in osteoblastsFEBS Letters, 2009
- An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilastCurrent Medical Research and Opinion, 2008
- Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatmentAnnals of the Rheumatic Diseases, 2006
- Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathwaysFEBS Letters, 2005
- cAMP elevators inhibit LPS-induced IL-12 p40 expression by interfering with phosphorylation of p38 MAPK in Murine Peritoneal MacrophagesCell Research, 2002